ArticleAnnals of thoracic surgery short reports2026
Artificial Intelligence Identification of Heart Failure With Preserved Ejection Fraction Substrate in Cardiac Surgery Patients.
Article in Annals of thoracic surgery short reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Outcomes for patients with heart failure with preserved ejection fraction (HFpEF) who are undergoing cardiac surgery are not clear. We sought to examine the impact of artificial intelligence (AI) -diagnosed HFpEF on cardiac surgical outcomes in low- to moderate-surgical risk patients. Methods: Adult patients undergoing isolated aortic valve replacement (AVR), mitral valve repair (MVr), or coronary artery bypass grafting (CABG) between 2004 and 2022 were retrospectively scored for the likelihood of HFpEF by using a commercially available echocardiogram-based AI algorithm. Patients with a left ventricular ejection fraction (LVEF)<50% were classified as having a reduced ejection fraction (HFrEF). On the basis of AI probabilities ranging from 0 to 1, patients with an LVEF ≥50% were stratified to normal function (0-0.49), moderate-probability HFpEF (0.5-0.74), and high-probability HFpEF (≥0.75). Results: Among 1882 patients, 86.6% (n = 1629) had an LVEF ≥50%; of those patients, 36.8% (n = 599) were in the high-probability HFpEF group (median LVEF, 60% [interquartile range {IQR}, 56%-65%]), 6.7% (n = 109) were in the moderate-probability HFpEF group (LVEF, 61% [IQR, 59%-65%]), and 56.5% (n = 921) had normal function (LVEF, 63% [IQR, 59%-66%]). The remaining 13.4% (n = 253) were in the HFrEF group (LVEF, 40% [IQR, 31%-45%]). Compared with normal function, high-probability HFpEF was associated with increased operative mortality (1.3% vs 0.3%; Conclusions: Using AI, we can identify patients with high-probability HFpEF at increased risk of adverse events. Identifying this subgroup may enable surgical teams to improve short- and long-term outcomes through guideline-directed medical therapy and warrants further study.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.